Rhesus factor Is a special protein found on the surface of red blood cells (erythrocytes). This protein is present in 85% of people who are called Rh-positive. If this protein is not present, then the blood is called Rh-negative.
If a Rh-negative woman becomes pregnant from a Rh-positive man and the fetus inherits Rh-belonging to the father, then a rhesus-conflict can develop.
In this case, the erythrocytes of the fetus penetrate into the blood of the pregnant woman, carrying a protein that is absent in the mother’s body. They, in essence, are alien to her, and therefore her body begins to develop protection, that is, Rh-antibody.
Rhesus antibodies penetrate into the bloodstream of the baby and destroy its red blood cells. This leads to oxygen deficiency, which affects all organs of the fetus, especially the heart and brain.
With a pronounced Rh-conflict, the fetus may die.
Developed in the body of women Rh-antibodies remain for life and burdens the course of subsequent pregnancies.
Until recently, doctors could not prevent the occurrence of Rhesus-conflict and therefore advised all women with Rh-negative blood to maintain their first pregnancy, since the risk of this pathology is minimal. Abortions were strictly contraindicated, since antibodies to the Rh factor begin to be produced in the early stages of pregnancy.
Now doctors have a reliable means to protect the woman and the fetus from Rh-conflict – anti-rheumatic immunoglobulin. One intramuscular injection reliably prevents the development of antibodies in the body of a future mother that threaten the health and life of her child.
In fact, this drug has existed for a long time. But because of its poor quality it was not recommended to be administered to pregnant women.
Now the situation has changed. Modern antirezusny immunoglobulin during pregnancy is absolutely safe and highly effective.
Women with Rhesus-negative blood should know that vaccination with an antiresusive immunoglobulin protects against the development of Rh-conflict only during one pregnancy. In subsequent pregnancies, the drug should be repeated.
Antirezusnyj an immunoglobulin – the instruction of application
Antiresusive immunoglobulin should be administered during pregnancy (first or subsequent) at a period of 28 weeks to all women with Rh-negative blood and provided they do not have Rh-antibodies. After birth, the introduction of the drug is repeated if the child was born with Rh-positive blood.